An economic case for a vaccine to prevent group A streptococcus skin infections.

[1]  J. Vekemans,et al.  Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016 , 2017, Vaccine.

[2]  Organización Mundial de la Salud.  World health statistics 2017: monitoring health for the SDGs, Sustainable Development Goals , 2018 .

[3]  Derek C. Angus,et al.  Enhancing Recovery From Sepsis: A Review , 2018, JAMA.

[4]  V. Saliba,et al.  Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. , 2017, The Lancet. Infectious diseases.

[5]  D. Speers,et al.  M protein gene (emm type) analysis of group A Streptococcus isolates recovered during an acute glomerulonephritis outbreak in northern Western Australia. , 2017, Pathology.

[6]  Andrea Beaton,et al.  Global, Regional, and National Burden of Rheumatic Heart Disease, 1990–2015 , 2017, The New England journal of medicine.

[7]  N. Wilson,et al.  Acute Rheumatic Fever After Group A Streptococcus Pyoderma and Group G Streptococcus Pharyngitis. , 2017, The Pediatric infectious disease journal.

[8]  Daniel Cadarette,et al.  PROGRAM ON THE GLOBAL DEMOGRAPHY OF AGING AT HARVARD UNIVERSITY Working Paper Series Moving beyond Traditional Valuation of Vaccination : Needs and Opportunities , 2016 .

[9]  M. Davies,et al.  Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development , 2016, BMC Infectious Diseases.

[10]  R. Lynfield,et al.  Epidemiology of Invasive Group A Streptococcal Infections in the United States, 2005-2012. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  J. Carapetis,et al.  Status of research and development of vaccines for Streptococcus pyogenes. , 2016, Vaccine.

[12]  S. Bâ,et al.  The VALVAFRIC study: A registry of rheumatic heart disease in Western and Central Africa. , 2016, Archives of cardiovascular diseases.

[13]  B. D. de Mol,et al.  Infections in early life and premature acute coronary syndrome: A case-control study , 2016, European journal of preventive cardiology.

[14]  R. Karron,et al.  Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015☆ , 2016, Vaccine.

[15]  P. Beutels,et al.  Retrospective economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Australia: Uncertain herd impact on pneumonia critical. , 2016, Vaccine.

[16]  P. Newton,et al.  Group A streptococcal strains isolated in Lao People's Democratic Republic from 2004 to 2013 , 2015, Epidemiology and Infection.

[17]  R. Hay,et al.  The Global Epidemiology of Impetigo: A Systematic Review of the Population Prevalence of Impetigo and Pyoderma , 2015, PloS one.

[18]  S. Dowd,et al.  Inability of polymerase chain reaction, pyrosequencing, and culture of infected and uninfected site skin biopsy specimens to identify the cause of cellulitis. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Dan J Stein,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[20]  M. Baker,et al.  Increasing incidence of invasive group A streptococcus disease in New Zealand, 2002-2012: a national population-based study. , 2015, The Journal of infection.

[21]  J. Carapetis,et al.  Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia's Northern Territory , 2015, Tropical medicine & international health : TM & IH.

[22]  M. Chatfield,et al.  The microbiology of impetigo in Indigenous children: associations between Streptococcus pyogenes, Staphylococcus aureus,scabies, and nasal carriage , 2014, BMC Infectious Diseases.

[23]  A. Walker,et al.  Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. , 2014, The Journal of infectious diseases.

[24]  Daan Van Brusselen,et al.  Streptococcal pharyngitis in children: to treat or not to treat? , 2014, European Journal of Pediatrics.

[25]  Jan V Hirschmann,et al.  Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  B. Mayosi,et al.  Group A Streptococcal emm Type Prevalence Among Symptomatic Children in Cape Town and Potential Vaccine Coverage , 2014, The Pediatric infectious disease journal.

[27]  B. Kuehn.  Excessive antibiotic prescribing for sore throat and acute bronchitis remains common. , 2013, JAMA.

[28]  M. Meehan,et al.  Increased incidence of invasive group A streptococcal disease in Ireland, 2012 to 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[29]  J. Carapetis,et al.  Acute Rheumatic Fever and Rheumatic Heart Disease: Incidence and Progression in the Northern Territory of Australia, 1997 to 2010 , 2013, Circulation.

[30]  B. Henriques-Normark,et al.  Increased incidence of invasive group A streptococcal infections in Sweden, January 2012-February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  J. Nataro,et al.  Potential coverage of a multivalent M protein-based group A streptococcal vaccine. , 2013, Vaccine.

[32]  J. Carapetis,et al.  Progress Toward a Global Group A Streptococcal Vaccine , 2013, The Pediatric infectious disease journal.

[33]  A. Ralph,et al.  Group a streptococcal diseases and their global burden. , 2013, Current topics in microbiology and immunology.

[34]  R. Gorton,et al.  Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England , 2012, Epidemiology and Infection.

[35]  J. Carapetis,et al.  Invasive Group a Streptococcal Disease , 2008 .

[36]  T. Penfound,et al.  New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci. , 2011, Vaccine.

[37]  Karl Claxton,et al.  Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.

[38]  L. Guilherme,et al.  A vaccine against S. pyogenes: design and experimental immune response. , 2009, Methods.

[39]  J. Carapetis,et al.  Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. , 2009, The Lancet. Infectious diseases.

[40]  L. Miller,et al.  Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review , 2009, Epidemiology and Infection.

[41]  J. Carapetis,et al.  High Burden of Impetigo and Scabies in a Tropical Country , 2009, PLoS neglected tropical diseases.

[42]  B. Henriques-Normark,et al.  Epidemiology of Severe Streptococcus pyogenes Disease in Europe , 2008, Journal of Clinical Microbiology.

[43]  D. Goldmann,et al.  Burden and Economic Cost of Group A Streptococcal Pharyngitis , 2008, Pediatrics.

[44]  J. Carlin,et al.  Burden of Acute Sore Throat and Group A Streptococcal Pharyngitis in School-aged Children and Their Families in Australia , 2007, Pediatrics.

[45]  J. Carapetis,et al.  The epidemiology of invasive group A streptococcal disease in Victoria, Australia , 2007, The Medical journal of Australia.

[46]  M. McDonald,et al.  Low rates of streptococcal pharyngitis and high rates of pyoderma in Australian aboriginal communities where acute rheumatic fever is hyperendemic. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  J. Carapetis,et al.  The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.

[48]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  R. George,et al.  Invasive group A streptococcal disease: should close contacts routinely receive antibiotic prophylaxis? , 2005, The Lancet. Infectious diseases.

[50]  M. Davies,et al.  Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. , 2003, The Journal of infectious diseases.

[51]  F. Shann,et al.  Systematic review of rheumatic heart disease prevalence in children in developing countries: The role of environmental factors , 2002, Journal of paediatrics and child health.

[52]  M. Reddish,et al.  Immunogenicity of a 26-Valent Group A Streptococcal Vaccine , 2002, Infection and Immunity.

[53]  P. Glasziou,et al.  Antibiotics for sore throat. , 2013, Nursing times.

[54]  M. Ferraz,et al.  Resource utilization and cost of rheumatic fever. , 2001, The Journal of rheumatology.

[55]  E. Kaplan,et al.  Streptococcal infections: clinical aspects, microbiology, and molecular pathogenesis. , 2000 .

[56]  P. Glasziou,et al.  Antibiotics for sore throat. , 2000, The Cochrane database of systematic reviews.

[57]  D. Shanson.  Microbiology in Clinical Practice , 1982 .